Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

When Eli Lilly reports its financial results early Thursday, investors will be looking for the company to press its advantage ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...

The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...

Wegovy and Zepbound - except the weight regain is worse, because of the extreme way in which these medications suppress your ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Trump administration officials are making statements that some advocacy and medical groups say depict patients and the ...